Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

NCT07459660 is registered in ClinicalTrials.gov with MapLight Therapeutics as lead sponsor.

NCT NCT07459660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07459660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML007C-MA in Adult Participants With Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis
Lead sponsor
MapLight Therapeutics
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
March 25, 2026
Completion date
March 31, 2029
Enrollment
210 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis associated with alzheimer's disease